CDT Equity Inc.
CDT Equity Inc.
- Market cap
- $11.41K
Your view on CDTTW
Overview
What the company does, where it operates, and who runs it.
About CDT Equity Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andrew Regan
- Headquarters
- 4581 Tamiami Trail North, Naples, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andrew Regan
- Headquarters
- 4581 Tamiami Trail North, Naples, FL, US
CDT Equity Inc., established in October 2021 by David Joszef Tapolczay and Freda C. Lewis-Hall, operates from its headquarters in Naples, Florida, with a core mission to advance the development and market introduction of clinical assets.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for CDT Equity Inc.. Starting points for CDT Equity Inc.: EPS $5903.62, beta 1.46 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for CDT Equity Inc.. Trailing twelve-month EPS for CDT Equity Inc. stands at $5903.62. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for CDT Equity Inc.. CDT Equity Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AKTXAkari Therapeutics, Plc | Healthcare | Biotechnology | $16.5M | ||
| BDRXBiodexa Pharmaceuticals Plc | Healthcare | Biotechnology | $174,870 | ||
| DRMADermata Therapeutics, Inc. | Healthcare | Biotechnology | $2.5M | ||
| MSPRMSP Recovery, Inc. | Healthcare | Medical - Healthcare Information Services | $1,377 | ||
| PBMPsyence Biomedical Ltd. | Healthcare | Biotechnology | $56,486 | ||
| PPBTPurple Biotech Ltd. | Healthcare | Biotechnology | $210,578 | ||
| REVBRevelation Biosciences, Inc. | Healthcare | Biotechnology | $2.0M | ||
| SLXNWSilexion Therapeutics Ltd. | Healthcare | Biotechnology | $36,808 | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ASPHFAscentage Pharma Group International | Healthcare | OTC | $3.2B | ||
| ATAIAtai Life Sciences N.V. | Healthcare | NASDAQ | $2.7B | ||
| ATGGFActinogen Medical Limited | Healthcare | OTC | $107.7M | ||
| ATH.AXAlterity Therapeutics Limited | Healthcare | ASX | — | ||
| ATHEAlterity Therapeutics Limited | Healthcare | NASDAQ | $25.8M | ||
| ATNMActinium Pharmaceuticals, Inc. | Healthcare | AMEX | $33.0M | ||
| ATOSAtossa Therapeutics, Inc. | Healthcare | NASDAQ | $15.9M | ||
| ATRAAtara Biotherapeutics, Inc. | Healthcare | NASDAQ | $64.5M | ||
| ATRXAdhera Therapeutics, Inc. | Healthcare | OTC | $722 | ||
| ATX.AXAmplia Therapeutics Limited | Healthcare | ASX | — | ||
| ATXIAvenue Therapeutics, Inc. | Healthcare | OTC | $2.5M | ||
| ATYRaTyr Pharma, Inc. | Healthcare | NASDAQ | $9.4M | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by CDT Equity Inc. executives and directors. Shares of CDT Equity Inc. have traded between $0.01 and $0.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for CDT Equity Inc.. Coverage tracks CDT Equity Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of CDT Equity Inc.